REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Quest Partners LLC

Quest Partners LLC lifted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 11,731.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 42,000 shares of the biotechnology company’s stock after buying an additional 41,645 shares during the period. Quest Partners LLC owned 0.09% of REGENXBIO worth $491,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Perceptive Advisors LLC purchased a new position in shares of REGENXBIO during the 4th quarter worth $6,146,000. Mirae Asset Global Investments Co. Ltd. lifted its position in REGENXBIO by 80.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 170,218 shares of the biotechnology company’s stock worth $3,586,000 after buying an additional 75,800 shares during the period. Virtu Financial LLC acquired a new stake in REGENXBIO in the 4th quarter worth about $377,000. ProShare Advisors LLC grew its holdings in REGENXBIO by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 874 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in shares of REGENXBIO by 174.4% during the 4th quarter. BNP Paribas Financial Markets now owns 67,760 shares of the biotechnology company’s stock valued at $1,216,000 after acquiring an additional 43,070 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analysts Set New Price Targets

RGNX has been the subject of a number of recent analyst reports. The Goldman Sachs Group initiated coverage on shares of REGENXBIO in a report on Friday, June 7th. They issued a “buy” rating and a $38.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $39.00 price objective on shares of REGENXBIO in a research note on Wednesday, September 4th. StockNews.com lowered REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, Barclays lowered their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.91.

Insider Buying and Selling at REGENXBIO

In other news, Director Kenneth T. Mills sold 2,210 shares of REGENXBIO stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $13.77, for a total transaction of $30,431.70. Following the sale, the director now directly owns 408,035 shares of the company’s stock, valued at $5,618,641.95. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other REGENXBIO news, Director Kenneth T. Mills sold 2,210 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $13.77, for a total transaction of $30,431.70. Following the completion of the sale, the director now owns 408,035 shares in the company, valued at approximately $5,618,641.95. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Kenneth T. Mills sold 12,221 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $13.78, for a total value of $168,405.38. Following the completion of the transaction, the director now directly owns 408,035 shares in the company, valued at $5,622,722.30. The disclosure for this sale can be found here. Insiders sold a total of 65,279 shares of company stock valued at $875,634 in the last ninety days. Insiders own 13.13% of the company’s stock.

REGENXBIO Stock Performance

RGNX stock opened at $12.18 on Friday. The firm has a market cap of $599.94 million, a P/E ratio of -2.07 and a beta of 1.22. REGENXBIO Inc. has a 1 year low of $10.49 and a 1 year high of $28.80. The stock has a 50-day simple moving average of $12.38 and a 200-day simple moving average of $15.37.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The business had revenue of $22.30 million during the quarter, compared to the consensus estimate of $22.97 million. During the same period in the prior year, the firm earned ($1.66) earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, equities research analysts predict that REGENXBIO Inc. will post -4.66 EPS for the current year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.